Research led by Indiana University School of Medicine and the University of Notre Dame shows a new treatment for peanut allergy is effective in a mouse model. The therapy, a covalent heterobivalent inhibitor (cHBI), differs from most allergy treatments in that it is more of a preventative therapy rather than a drug to treat immediate acute symptoms.